KRAS基因变异致Noonan综合征3型1例及临床表型谱分析

doi:10.3760/cma.j.cn441417-20250408-18016

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (18): 3076-3080.DOI: 10.3760/cma.j.cn441417-20250408-18016

KRAS基因变异致Noonan综合征3型1例及临床表型谱分析

李鑫¹ 王振竞¹ 綦才辉¹ 刘欣¹ 杨文涛² 王淑萍¹

¹东营市人民医院（山东省立集团东营医院）内分泌科东营市内分泌代谢病分子诊断重点实验室，东营 257091；²东营市人民医院（山东省立集团东营医院）急诊科，东营 257091

收稿日期:2025-04-08 出版日期:2025-09-15 发布日期:2025-09-26
通讯作者: 杨文涛，Email：ywentao2010@163.com；王淑萍，Email：renzhendoctor@163.com
基金资助:
山东省医药卫生科技发展计划（202103060606，2018WS520）；东营市自然科学基金（2023ZR018，2024ZRWS031）

One case of Noonan syndrome type 3 caused by KRAS gene mutation and analysis of clinical phenotypic spectrum

Li Xin¹, Wang Zhenjing¹, Qi Caihui¹, Liu Xin¹, Yang Wentao², Wang Shuping¹

¹Department of Endocrinology, Dongying People's Hospital (Dongying Hospital, Shandong Provincial Hospital Group), Dongying Key Laboratory of Molecular Diagnosis for Endocrinological and Metabolic Diseases, Dongying 257091, China; ²Department of Emergency, Dongying People's Hospital (Dongying Hospital, Shandong Provincial Hospital Group), Dongying, 257091, China

Received:2025-04-08 Online:2025-09-15 Published:2025-09-26
Contact: Yang Wentao, Email: ywentao2010@163.com; Wang Shuping, Email:renzhendoctor@163.com
Supported by:
Shandong Provincial Medical and Health Science and Technology Development Program (202103060606 and 2018WS520); Natural Science Foundation of Dongying City (2023ZR018 and 2024ZRWS031)

摘要/Abstract

摘要：

目的　探讨1例KRAS基因变异致Noonan综合征3型的临床特征和基因变异情况，为该病诊断提供参考。方法　选择2024年8月在东营市人民医院就诊的1例15岁2个月的Noonan综合征3型男性患者。采用回顾性研究方法，收集患者的相关临床资料，对患者及其父母外周血样进行全外显子测序，对候选变异进行Sanger测序验证和生物信息学分析。根据美国医学遗传学与基因学学会（American College of Medical Genetics and Genomic，ACMG）制定的《遗传变异分类标准与指南》，对该变异进行致病性评级。结果　患者临床特征为身材矮小、生长发育迟缓、面部畸形、心电图异常等。全外显子测序显示KRAS基因为新发致病性点突变：NM_004985.4：c.40G>A（Val14Ile）。根据ACMG相关指南评判为致病变异（PS2_VeryStrong+PS3+PS4+PM1+PP2+PM2_Supporting）。结论　KRAS基因新发变异考虑为Noonan综合征3型患者的遗传学病因。对身材矮小、生长发育迟缓、面部畸形、心电图异常的患者，应警惕Noonan综合征3型的可能，通过基因检测尽早明确诊断。本研究的发现亦扩展了KRAS基因的变异谱。

关键词:

Noonan综合征3型, KRAS基因, 表型谱

Abstract:

Objective　To explore the clinical features and genetic variants in a case of KRAS gene mutation-induced Noonan syndrome type 3, and to provide some references for its diagnosis. Methods　We selected a case of a 15-year-and-2-month-old male patient with Noonan syndrome type 3 who visited Dongying People's Hospital in August 2024. The patient's clinical data were retrospectively collected. Whole-exome sequencing was performed on the peripheral blood samples from the patient and his parents. The candidate variants were validated by Sanger sequencing, and analyzed by the bioinformatics tools. The pathogenicity of the identified variant was classified according to the standards and guidelines for the interpretation of sequence variants established by the American College of Medical Genetics and Genomics (ACMG). Results　The patient's clinical features included short stature, growth and developmental delay, facial dysmorphism, and electrocardiographic abnormalities. The whole-exome sequencing revealed a de novo pathogenic point mutation in the KRAS gene: NM_004985.4: c.40G>A (p.Val14Ile). According to the ACMG guidelines, the variant was classified as pathogenic (PS2_VeryStrong+PS3+PS4+PM1+PP2+PM2_Supporting). Conclusions　The de novo variant in the KRAS gene is considered the genetic etiology of Noonan syndrome type 3 in this patient. For children with short stature, growth and developmental delay, facial dysmorphism, or electrocardiographic abnormalities, clinical suspicion for Noonan syndrome type 3 should be raised, and early genetic testing is recommended to confirm the diagnosis. The findings of this study also expand the known variant spectrum of the KRAS gene.

Key words:

Noonan syndrome type 3, KRAS , gene, Phenotype spectrum

李鑫王振竞綦才辉刘欣杨文涛王淑萍.

KRAS基因变异致Noonan综合征3型1例及临床表型谱分析 [J]. 国际医药卫生导报, 2025, 31(18): 3076-3080.

Li Xin, Wang Zhenjing, Qi Caihui, Liu Xin, Yang Wentao, Wang Shuping.

One case of Noonan syndrome type 3 caused by KRAS gene mutation and analysis of clinical phenotypic spectrum [J]. International Medicine and Health Guidance News, 2025, 31(18): 3076-3080.

参考文献

[1] Vinkhuyzen AA, Wray NR, Yang J, et al. Estimation and partition of heritability in human populations using whole-genome analysis methods[J]. Annu Rev Genet, 2013, 47: 75-95. DOI: 10.1146/annurev-genet-111212-133258.
[2] Siegfried A, Cances C, Denuelle M, et al. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature [J]. Am J Med Genet A, 2017, 173(4):1061-1065. DOI: 10.1002/ajmg.a.38108.
[3] Aoki Y, Niihori T, Banjo T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome [J]. Am J Hum Genet, 2013, 93(1):173-80. DOI: 10.1016/j.ajhg.2013.05.021.
[4] Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) [J]. Genet Med, 2023, 25(8):100866. DOI: 10.1016/j.gim.2023.100866.
[5] Costain G, Walker S, Marano M, et al. Genome sequencing as a diagnostic test in children with unexplained medical complexity[J]. JAMA Netw Open, 2020, 3(9): e2018109. DOI: 10.1001/jamanetworkopen.2020.18109.
[6] Lo FS, Lin JL, Kuo MT, et al. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature[J]. Eur J Pediatr, 2009, 168(8): 919-923. DOI: 10.1007/s00431-008-0858-z.
[7] Monies D, Abouelhoda M, Assoum M, et al. Lessons learned from large-scale, first-tier clinical exome sequencing in a highly consanguineous population[J]. Am J Hum Genet, 2019, 104(6):1182-1201. DOI: 10.1016/j.ajhg.2019.04.011.
[8] Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome[J]. Nat Genet, 2006, 38(3):331-336. DOI: 10.1038/ng1748.
[9] Gremer L, Merbitz-Zahradnik T, Dvorsky R, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders[J]. Hum Mutat, 2011, 32(1): 33-43. DOI: 10.1002/humu.21377.
[10] Gelb BD, Cavé H, Dillon MW, et al. ClinGen's RASopathy expert panel consensus methods for variant interpretation[J]. Genet Med, 2018, 20(11):1334-1345. DOI: 10.1038/gim.2018.3.
[11] 赵倩倩,张梅,李艳英,等. Noonan综合征患儿PTPN11基因突变的临床及遗传分析[J]. 中华内分泌代谢杂志,2022,38(9):775-780. DOI:10.3760/cma.j.cn311282-20211120-00742.
[12] 张文,林云婷,李端,等. 17例Noonan综合征临床表型与基因型特点[J]. 重庆医科大学学报, 2022, 47(3):300-305. DOI:10.13406/j.cnki.cyxb.002989.
[13] 禹超南,吕楠,李东晓,等.RRAS基因新发变异致Noonan综合征1例病文献复习[J/OL].中国临床案例成果数据库, 2023,5(1):E00740-E00740. DOI:10.3760/cma.j.cmcr.2023.e00740.
[14] Denayer E, Legius E. What's new in the neuro-cardio-facial-cutaneous syndromes? [J]. Eur J Pediatr, 2007, 166(11):1091-1098. DOI: 10.1007/s00431-007-0535-7.
[15] Fryssira H, Leventopoulos G, Psoni S, et al. Tumor development in three patients with Noonan syndrome[J]. Eur J Pediatr, 2008, 167(9): 1025-1031. DOI: 10.1007/s00431-007-0636-3.
[16] 郝鹏锴,刘梦南,朱颖杰,等. MRAS基因突变相关Noonan综合征1例报道并文献复习[J]. 国际医药卫生导报,2024,30(22):3743-3746. DOI:10.3760/cma.j.issn.1007-1245.2024.22.011.

KRAS基因变异致Noonan综合征3型1例及临床表型谱分析

One case of Noonan syndrome type 3 caused by KRAS gene mutation and analysis of clinical phenotypic spectrum

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics